Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “C3 Glomerulopathy”

33 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 33 results

Testing effectiveness (Phase 2)Ended earlyNCT02682407
What this trial is testing

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Who this might be right for
IgANLNMN+1 more
Omeros Corporation 31
Testing effectiveness (Phase 2)Study completedNCT03124368
What this trial is testing

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

Who this might be right for
C3 GlomerulonephritisDense Deposit DiseaseC3 Glomerulopathy+2 more
Alexion Pharmaceuticals, Inc. 6
Testing effectiveness (Phase 2)Ended earlyNCT03459443
What this trial is testing

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Alexion Pharmaceuticals, Inc. 22
Not applicableActive Not RecruitingNCT07156149
What this trial is testing

Fabhalta Capsules Specified Drug-use Survey

Who this might be right for
C3 Glomerulopathy
Novartis Pharmaceuticals 33
Testing effectiveness (Phase 2)Study completedNCT03095118
What this trial is testing

Daratumumab in Treatment of PGNMID and C3 GN

Who this might be right for
Membranoproliferative Glomerulonephritis
Fernando Fervenza 12
Early research (Phase 1)Looking for participantsNCT07483827
What this trial is testing

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

Who this might be right for
C3 Glomerulopathy (C3G)Healthy Adult Participants
eleva GmbH 39
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07730632
What this trial is testing

Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)

Who this might be right for
IgAN - IgA NephropathyImmune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 Glomerulopathy (C3G)+1 more
Qilu Pharmaceutical Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT03832114
What this trial is testing

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Who this might be right for
Glomerulonephritis
Novartis Pharmaceuticals 27
Testing effectiveness (Phase 2)Study completedNCT03301467
What this trial is testing

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Who this might be right for
C3 Glomerulopathy (C3G)
Amgen 57
Large-scale testing (Phase 3)Looking for participantsNCT03955445
What this trial is testing

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Who this might be right for
C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals 225
Large-scale testing (Phase 3)Looking for participantsNCT04817618
What this trial is testing

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Who this might be right for
C3G
Novartis Pharmaceuticals 98
Not applicableNot Yet RecruitingNCT06851845
What this trial is testing

Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

Who this might be right for
Kidney Diseases
Novartis Pharmaceuticals 100
Testing effectiveness (Phase 2)Study completedNCT04572854
What this trial is testing

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Who this might be right for
C3GIC-MPGNRenal Transplant+9 more
Apellis Pharmaceuticals, Inc. 13
Testing effectiveness (Phase 2)Study completedNCT05083364
What this trial is testing

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Who this might be right for
C3 GlomerulopathyIgA Nephropathy
Arrowhead Pharmaceuticals 62
Not applicableLooking for participantsNCT07029542
What this trial is testing

Home Reported Outcomes in C3G Study

Who this might be right for
C3 Glomerulopathy
Novartis Pharmaceuticals 100
Testing effectiveness (Phase 2)Looking for participantsNCT06209736
What this trial is testing

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Who this might be right for
C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corporation 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05647811
What this trial is testing

Study of NM8074 in Adult C3 Glomerulopathy Patients

Who this might be right for
C3 Glomerulopathy
NovelMed Therapeutics 18
Not applicableLooking for participantsNCT06065852
What this trial is testing

National Registry of Rare Kidney Diseases

Who this might be right for
Adenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more
UK Kidney Association 35,000
Not applicableStudy completedNCT03723512
What this trial is testing

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Mario Negri Institute for Pharmacological Research 7
Early research (Phase 1)Study completedNCT03316521
What this trial is testing

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50
Next Page